Status message

Active context: kki_bg_colors_yellow

Retrospective analysis of risk factors associated with auditory processing disorder: SCAN-3 vs. LiSN-S

Principal Investigator:

Due to their complexity and variability, disorders involving auditory processing lack a consistent definition and diagnostic criteria. These disorders are characterized by difficulty comprehending of auditory stimuli, despite normal mechanical auditory functioning of the inner and outer ears. However, the exact neurological mechanism that is flawed, and the precise degree of processing limitation vary among patients, and are often unknown. Recognizing this lack of diagnostic precision, the current diagnostic term utilized is CAPD (Central Auditory Processing Disorders). Typically, children with CAPD pass the standard audiogram, indicating normal peripheral auditory functioning. However, there is also variability between providers and clinical centers in the battery of testing used to evaluate central processing. Further, the underlying mechanisms of CAPD remains unclear, making it difficult to distinguish whether CAPD is a comorbid condition within the context of developmental and behavioral disorders such as ADD and ADHD, or whether it is an independent neurological disorder.

The unclear physiology of CAPD and its lack of a standard differential diagnosis pattern are self-perpetuating issues that complicate treatment. The recent development of the Listening in Spatialized Noise – Sentences Test (LiSN-S) auditory processing test shows potential as a new diagnostic test. We propose a retrospective study whose participants are children previously diagnosed with CAPD at the Kennedy Krieger Institute in Baltimore, MD. Testing to characterize performance include both LisN-S and SCAN-3. The children’s test results on the LiSN-S test will be compared with their performance on the more traditional SCAN-3 test scores to assess whether there is a consistent significant correlation between these two tests. In addition, the relationship between CAPD and other risk factors will be examined to determine whether results on one of the tests can subdivide CAPD patients based on specific risk factors.

Bradley L. Schlaggar, M.D., Ph.D., Named President and CEO of Kennedy Krieger Institute

We’re thrilled to welcome Bradley L. Schlaggar, M.D., Ph.D., to the Kennedy Krieger family as our next President and CEO.
Learn more.


Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.